Global Pruritus Therapeutics Market Growth 2024, Forecast To 2033
8 Mar, 2024
The pruritus therapeutics market has shown robust growth, climbing from $11.39 billion in 2023 to $12.03 billion in 2024 (CAGR: 5.6%), driven by rising incidence and aging demographics. Anticipated expansion to $14.99 billion in 2028 (CAGR: 5.6%) is expected, fueled by advancements in understanding its pathophysiology and personalized treatments. Major trends include the development of itch-specific treatments and integration of technology for monitoring and management.
Global Pruritus Therapeutics Market Key Driver
The pruritus therapeutics market is expanding due to the rising incidence of dermatological disorders. With an increasing number of skin cancer cases, there's a growing need for therapeutics to address itching associated with various dermatological conditions, as indicated by data from the American Cancer Society Inc.
Get A Free Sample Of The Global Pruritus Therapeutics Market ReportGlobal Pruritus Therapeutics Market Segments
The pruritus therapeutics market covered in this report is segmented –
1) Product:Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products
2) Route of Administration:Oral, Parenteral, Topical
3) Disease Type:Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types
4) End-User:Hospitals, Clinics, Other End Users
By Geography: The countries covered in the pruritus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the pruritus treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Pruritus Therapeutics Industry Players
Pfizer Inc.; Johnson & Johnson; AbbVie Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; Abbott Laboratories; Eli Lilly and Company; Amgen Inc. ; Regeneron Pharmaceuticals Inc.; Astellas Pharma Inc. ; Bausch Health Companies Inc.; Brunswick Corporation; Galderma Laboratories LP; Cipla Limited; Vifor Pharma Ltd.; Carl Zeiss Meditec AG; LEO Pharma AS; Mirum Pharmaceuticals Inc.; Cara Therapeutics Inc.; GlaxoSmithKline Plc; Novan Inc.; Escient Pharmaceuticals Inc.; Nerre Therapeutic Ltd.; EPI Health LLC; Trevi Therapeutics Inc.; Evelo Biosciences; Toray Medical Co. Ltd.
Get The Full Global Pruritus Therapeutics Market Report
Pruritus Therapeutics Market Overview
Pruritus therapeutics refers to the treatments used to address an unpleasant skin sensation that causes an urge to scratch. This treatment is commonly used to stop swelling and inflammation in moderate-to-severe inflammatory skin diseases.